Innocan Pharma Corporation: Innocan Pharma Provides Annual State of the Business Update

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - February 16, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology

Related Keywords

Germany ,Jerusalem ,Israel General ,Israel ,United States ,Herzliya ,Tel Aviv ,Canada ,Canadian ,Merav Shamir ,Dennis Riedl ,Iris Bincovich ,Nissim Vasilevski ,Kenji Kitatani ,Eva Reuter ,Eyal Kalo ,Company Or Innocan ,Additional Research ,Drug Administration ,Innocan Pharma Corporation ,Bi Sky Global Ltd ,Koret School Of Veterinary Medicine Hospital ,Biohouse Labs At Hadassah Medical Center ,Hebrew University Of Jerusalem ,Company The Options ,Company Activity Under Research Agreements ,Alberta Newsfile Corp ,Sony Corporation ,Canadian Securities Exchange ,Pharma Corporation ,Intellectual Property ,Activity Under Research Agreements ,Yissum Research Development Company ,Hebrew University ,Second Amendment ,Professor Merav Shamir ,Koret School ,Veterinary Medicine Hospital ,Biohouse Labs ,Hadassah Medical Center ,Veterinary Science ,Innocan Pharma ,Cannabinoid Formulations ,Based Topical Compositions ,Classb Warrant ,Common Share ,Common Shares ,United States Securities Act ,Central Nervous System ,Consumer Wellness ,Joint Venture ,Innocan ,Dharma ,Corporation ,Rovides ,Nnual ,Estate ,Business ,Update ,